← SynDRA
RAUWOLSCINE
SynDRA canonical compound SYN0000416 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | HTR2B |
|---|
| Mechanism of action | Adrenergic receptor antagonist |
|---|
All known targets
- ADRA2B
- ADRA2C
- HTR2B
- ADRA2A
- HTR1B
- HTR1D
- HTR1A
- HTR1E
Mechanisms of action (all sources)
- Adrenergic receptor antagonist
- ADRA2B ANTAGONIST
- ADRA2C ANTAGONIST
- HTR2B ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- HRH1
- HTR6
- SIGMAR1
- DRD2
- HTR7
- ADRA1A
- ADRA1D
- ADRA1B
- DRD3
- HTR3A
- HTR5A
- KCNH2
- MPG
- NEIL1
- NEIL2
- OGG1
- OPRD1
- OPRM1
- OPRK1
- HTR2A
- PMP22
- POLI
- RGS4
- S1PR1
- SLC6A2
- SLC6A3
- SLC6A4
- SLCO1B1
- SLCO1B3
- TDG
- TMEM97
- HTR2C
- ADGRF1
- HRH4
- CHRM5
- ADRB1
- ADRB2
- AGTR1
- APEX1
- APLNR
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- 5HT1B
- 5HT1D
- 5HT1E
- 5HT2B
- ADA2B
- ADA2C
- AHR
- TADA2A
Cross-references
Synonyms
- [3H]rauwolscine
- alpha-Yohimbine
- Mesoyohimbine
- Isoyohimbine
- Corynanthidine
- UNII-T4LJ7LU45W
- Methyl (16beta,17alpha,20alpha)-17-hydroxyyohimban-16-carboxylate
- T4LJ7LU45W
- CHEMBL10347
- CHEBI:48562
- 17alpha-hydroxy-20alpha-yohimban-16beta-carboxylic acid methyl ester
- NCGC00017260-05
- methyl 17alpha-hydroxy-20alpha-yohimban-16beta-carboxylate
- 17-alpha-Hydroxy-20-alpha-yohimban-16-beta-carboxylic acid methyl ester
- EINECS 205-006-9
- 20-alpha-Yohimban-16-beta-carboxylic acid, 17-alpha-hydroxy-, methyl ester
- yohimbine
- DTXCID0025608
- RefChem:930571
- meso-Yohimbine
- methyl hydroxy[?]carboxylate
- SR-01000075289
- .alpha.-Yohimbine
- |_-Yohimbine
- I+/--Yohimbin
- Spectrum_001458
- Prestwick0_000577
- Prestwick1_000577
- Prestwick2_000577
- Prestwick3_000577
- Spectrum2_000870
- Spectrum3_001761
- Spectrum4_000319
- Spectrum5_001121
- Rauwolscine (6CI,7CI)
- Rauwolscine;[3H]rauwolscine
- Lopac0_001093
- BSPBio_000394
Look up RAUWOLSCINE in the interactive SynDRA portal →